Showing 721-730 of 2222 results for "".
- New Recommendations on Glucocorticoid Treatment for People with Neuromuscular Disordershttps://practicalneurology.com/news/new-guidelines-published-for-glucocorticoid-treatment-for-people-with-neuromuscular-disorders/2474507/A multidisciplinary expert panel has released new consensus-based recommendations on glucocorticoid use for people with neuromuscular disorders, aiming to streamline clinical decisions amid a lack of specific, formal guidelines. Published in Muscle and Nerve, the guidance aims to support safer, m
- Wrist-Worn Neurostimulation Device for Hand Movement Rehabilitation after Stroke or Spinal Injury Receives FDA Clearancehttps://practicalneurology.com/news/wrist-worn-neurostimulation-device-for-hand-movement-rehabilitation-after-stroke-or-spinal-injury-receives-fda-clearance/2473788/The Food and Drug Administration (FDA) has granted 510(K) clearance to NeuStim (Neuvotion, Stamford, CT), a noninvasive, surgery-free wearable neurostimulation device used to aid in hand movement recovery in patients who have experienced a stroke or spinal cord injury (SCI). The device can scan m
- Eight Potential Alternative/Off-Label Treatments for ALS Identified by Researchershttps://practicalneurology.com/news/eight-potential-alternativeoff-label-treatments-for-als-identified-by-researchers/2473774/Researchers have identified 8 alternative and off-label treatments (AOTs) which may have efficacy for targeting some of the multiple, overlapping pathogenic mechanisms thought to underly amyotrophic lateral sclerosis (ALS), such as neuroinflammation, oxidative stress, mitochondrial dysfunction, m
- NFL Players Wear Cleats to Support Muscular Dystrophy Associationhttps://practicalneurology.com/news/the-muscular-dystrophy-society-represented-in-the-nfls-my-cause-my-cleats-campaign/2470660/During the “My Cause My Cleats” campaign, which took place during the first 2 weeks of December, several National Football League (NFL) players wore custom-designed cleats to support causes important to them. Nyheim Hines, 2024 Muscular Dystrophy Association (M
- Frailty Linked to Greater Risk of Dementiahttps://practicalneurology.com/news/frailty-linked-to-greater-risk-of-dementia/2470643/Frailty measurements may enable the identification of individuals at higher risk of dementia up to 9 years before the onset of the disorder, according to study results published in JAMA Neurology. According to the study authors, the findings demonstrate the potential utility of frailty m
- American Epilepsy Society Establishes Travel Award for Studentshttps://practicalneurology.com/news/aes-establishes-travel-grant-for-students/2470638/The American Epilepsy Society (AES) has established the Eileen M. Murray, MM, CAE, First-Generation Travel Award, consisting of a $1000 travel stipend and complimentary registration to the AES Annual Meeting. The award is intended to support first-generation medical, graduate, nursing, pharmacy,
- Study Compares FUS Unilateral Thalamotomy vs FUS Subthalamotomy in People with Medication Refractory Tremorhttps://practicalneurology.com/news/study-compares-fus-unilateral-thalamotomy-vs-fus-subthalamotomy-in-people-with-medication-refractory-tremor/2470600/Research presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders compared the effects of unilateral focused ultrasound subthalamotomy (FUS-STN) with unilateral focused ultrasound of the ventral intermediate thalamic nucleus (FUS-Vim) in participants with m
- FDA Clears Wearable Electrophysiological Monitoring Patch to Record EEG, EOG, EMG, and EKG Datahttps://practicalneurology.com/news/fda-clears-wearable-electrophysiological-monitoring-patch-to-measure-eeg-eog-emg-and-ekg-signals/2470409/The Food and Drug Administration (FDA) has granted 510(k) clearance to Smart Skin (X-trodes System M; X-trodes, Tel Aviv, Israel). Smart Skin is a wireless wearable system for medical-grade electrophysiological monitoring for at-home use, available as a dry-printed multi-modal electrode patch. Th
- Access to Care and Hispanic Cultural Attitudes Regarding Epilepsyhttps://practicalneurology.com/news/access-to-care-and-hispanic-cultural-attitudes-regarding-epilepsy/2469772/Research on attitudes and perceptions toward health care amongst diverse groups of people is required to address social determinants of health that lead to health care disparities in the US. Findings from virtual focus groups of people with epilepsy, living in Texas and California and reporting M
- Perampanel as Monotherapy or First Adjunctive Therapy Effectively Reduced Seizures in a Phase 4 Studyhttps://practicalneurology.com/news/perampanel-as-monotherapy-or-first-adjunctive-therapy-effectively-reduced-seizures-in-a-phase-4-study/2469771/In the ELEVATE study (NCT03288129), 63% (34/54) of individuals, age 4 or more, who were treated with perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) as monotherapy or a first adjunctive therapy continued treatment over a 12-month period. The retention rate was higher when perampanel was used as m